Last reviewed · How we verify
Tenoten
Tenoten, marketed by Materia Medica Holding, is a drug with a well-established presence in its primary indication. The key composition patent for Tenoten is set to expire in 2028, providing a significant period of market exclusivity. The primary risk for Tenoten is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Tenoten |
|---|---|
| Sponsor | Materia Medica Holding |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children (PHASE3)
- Efficacy and Safety of Tenoten in the Treatment of Children With Anxiety Disorders (PHASE4)
- Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders (PHASE4)
- Efficacy and Safety Clinical Trial of Tenoten for Children Liquid Dosage Form Therapy in Infants With Sequelae of Perinatal Brain Injury (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenoten CI brief — competitive landscape report
- Tenoten updates RSS · CI watch RSS
- Materia Medica Holding portfolio CI